Suspension of trading

NeuBase Therapeutics, Inc. Stock

O7P

US64132K2015

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG Other stock markets 02:03:16 2024-05-13 EDT			5-day change	1st Jan Change
0.3406 ^EUR	-0.58%		-.--%	-

25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI

Valuation: NeuBase Therapeutics, Inc.

Market Cap	1.28M 1.12M 1.03M 950K 1.79M 123M 1.83M 12.32M 4.84M 60.27M 4.8M 4.69M 207M	P/E 2023 *	-	P/E 2024 *	-
Enterprise Value	1.28M 1.12M 1.03M 950K 1.79M 123M 1.83M 12.32M 4.84M 60.27M 4.8M 4.69M 207M	EV / Sales 2023 *	-	EV / Sales 2024 *	-
Free-Float	86.62%	Yield 2023 *	-	Yield 2024 *	-

* Estimated data More valuation ratios

Latest news : NeuBase Therapeutics, Inc.

25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI
24-06-27	NeuBase Therapeutics, Inc. Announces Board Resignations	CI
24-05-28	NeuBase Therapeutics, Inc. announced that it has received $0.000001 million in funding	CI

More news

Managers and Directors: NeuBase Therapeutics, Inc.

Manager	Title	Age	Since
Ron Sarkar PRN	Corporate Officer/Principal	-	2021-10-31

Director	Title	Age	Since
Todd Branning BRD	Director/Board Member	56	2025-01-03

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEUBASE THERAPEUTICS, INC.	-0.58%	-.--%	-.--%	-77.85%	1.39M
LONZA GROUP AG	-1.29%	-3.11%	-0.39%	+4.92%	49.7B
REVOLUTION MEDICINES, INC.	+3.90%	-0.39%	+376.72%	+599.59%	38.09B
BEONE MEDICINES AG	-1.70%	+4.46%	+7.46%	+57.67%	35.29B
IQVIA HOLDINGS INC.	-2.01%	-0.76%	+26.35%	-6.83%	35.13B
CELLTRION, INC.	+0.06%	+0.34%	+2.32%	+29.30%	27.22B
ASCENDIS PHARMA A/S	+0.46%	-3.49%	-	-	16.14B
MEDPACE HOLDINGS, INC.	-0.04%	-0.09%	+68.48%	+117.39%	15.36B
EUROFINS SCIENTIFIC SE	+1.12%	+1.91%	+15.90%	+19.65%	13.89B
ICON PUBLIC LIMITED COMPANY	0.00%	+1.36%	+15.74%	-30.62%	13.02B
Average	-0.01%	-0.79%	+56.95%	+79.24%	24.38B
Weighted average by Cap.	-0.09%	-0.72%	+74.93%	+120.13%

See all sector performances

NeuBase Therapeutics, Inc. is a United States-based preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Companyâ€™s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntingtonâ€™s disease (HD), and oncology and in gene editing applications.

Employees

Sector

Biotechnology & Medical Research

More about the company